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ABSTRACT: Bone loss associated with menopause leads to an increase in skeletal fragility and fracture risk.
Relevant animal models can be useful for evaluating the impact of ovarian failure on bone loss. A chemically
induced model of menopause in which mice gradually undergo ovarian failure yet retain residual ovarian tissue
has been developed using the chemical 4-vinylcyclohexene diepoxide (VCD). This study was designed to
compare skeletal effects of VCD-induced ovarian failure to those associated with ovariectomy (OVX). Young
(28 day) C57Bl/6Hsd female mice were dosed daily with vehicle or VCD (160 mg/kg/d, IP) for 15 days (n 
6–7/group) and monitored by vaginal cytology for ovarian failure. At the mean age of VCD-induced ovarian
failure (∼6 wk after onset of dosing), a different group of mice was ovariectomized (OVX, n  8). Spine
BMD (SpBMD) was measured by DXA for 3 mo after ovarian failure and OVX. Mice were killed ∼5 mo after
ovarian failure or OVX, and bone architecture was evaluated by CT ex vivo. In OVX mice, SpBMD was
lower than controls 1 mo after OVX, whereas in VCD-treated mice, SpBMD was not lower than controls until
2.9 mo after ovarian failure (p < 0.05). Both VCD-induced ovarian failure and OVX led to pronounced
deterioration of trabecular bone architecture, with slightly greater effects in OVX mice. At the femoral
diaphysis, cortical bone area and thickness did not differ between VCD mice and controls but were decreased
in OVX compared with both groups (p < 0.05). Circulating androstenedione levels were preserved in VCD-
treated mice but reduced in OVX mice relative to controls (p < 0.001). These findings support that (1)
VCD-induced ovarian failure leads to trabecular bone deterioration, (2) bone loss is attenuated by residual
ovarian tissue, particularly in diaphyseal cortical bone, and (3) the VCD mouse model can be a relevant model
for natural menopause in the study of associated bone disorders.
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INTRODUCTION
M
ENOPAUSE IN WOMEN occurs when functional ovarian
follicles become depleted. At that time, ovarian pro-
duction of 17-estradiol, progesterone, and inhibin mark-
edly decreases.
(1) After menopause, there is a rapid phase
of bone loss and bone microarchitectural deterioration that
may last for 5–10 yr, followed by a slower rate of bone loss
that continues indefinitely.
(2) The classical view of the
mechanism underlying bone loss and increased skeletal fra-
gility involves the gradual decline in 17-estradiol produc-
tion.
(3,4) The cellular basis for these skeletal changes in-
cludes enhanced bone turnover, with the balance favoring
osteoclast mediated resorption in the absence of estro-
gen.
(4,5) Recent data indicate that, in addition to estrogen,
other factors that are altered in the perimenopausal and
menopausal periods, such as increased follicle stimulating
hormone (FSH) and decreased inhibin, may also directly
affect bone metabolism. Changes in gonadal inhibins likely
have direct effects on osteoblast and osteoclast activity
across the menopausal transition and can be associated with
increased bone turnover independent of changes in sex ste-
roids or FSH.
(6–8) FSH enhances osteoclast development
and survival in vitro, and increased FSH has been reported
to be a better predictor of increased bone resorption and
decreased BMD than 17-estradiol.
(9–12)
Despite the profound impact of menopause on women’s
health, animal models that mimic the natural progression
through perimenopause and into the postmenopausal
stages are currently lacking. Ovariectomy (OVX), or surgi-
cal removal of the ovaries, is the most common animal
model for studying the mechanisms that underlie the skel-
etal response to estrogen deficiency. Although widely used,
OVX is problematic with regard to reproducing the effects
of natural menopause. OVX produces a rapid, dramatic
cessation of ovarian function, rather than the gradual de-
cline that occurs in perimenopause. During an early natural
menopausal period, inhibin secretion by the ovaries de-
clines, leading to a rise in FSH in the presence of waning
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JO711697 1296 1303 August17-estradiol levels. The combined effect of gradual
changes in these hormonal factors on skeletal health cannot
be examined in an ovary-deficient animal. Finally, the post-
menopausal ovary continues to produce low levels of an-
drostenedione, a hormone known to have bone protective
effects, which is not produced in rodents after surgical re-
moval of the ovaries.
(13)
A chemically induced mouse model for peri- and post-
menopause has been developed using the occupational
chemical, 4-vinylcyclohexene diepoxide (VCD).
(14–16)
VCD selectively destroys ovarian small preantral follicles
after repeated daily dosing in mice and rats.
(17,18) The
mechanism of VCD’s highly selective effect on ovarian pre-
antral follicles has been shown in previous studies to be
caused by acceleration of the natural process of atresia (ap-
optosis) through follicle-specific pathways, with no evi-
dence of necrotic changes in ovarian tissue or changes in
gene expression that cannot be attributed to ovarian fail-
ure.
(19–23) Evidence for VCD’s lack of toxicity to other tis-
sues or organ systems was published in early work by the
National Toxicology Program. In these studies, rats and
mice repeatedly exposed to VCD for 2 yr showed that
(other than skin lesions at the site of repeated dermal ap-
plication) the only notable effects were in female ovaries,
and no other systems were impacted by this chronic expo-
sure.
(24) Because of selectivity of its effects, VCD has been
used to cause premature ovarian failure after repeated daily
dosing in rodents.
(14) After the destruction of preantral fol-
licles, the onset of VCD-induced ovarian failure is associ-
ated with fluctuating 17-estradiol, increasing FSH levels,
and irregular estrous cyclicity (i.e., a model for perimeno-
pause).
(15,16) Additionally, unlike OVX animals generally
used to model menopause, the VCD-treated animal retains
residual ovarian tissue (i.e., a model for natural meno-
pause).
(14)
Effects of the VCD-induced model of ovarian failure on
bone integrity have yet to be compared with the effects of
OVX-induced bone loss. We first evaluated the short-term
effects of VCD on bone microarchitecture and then com-
pared the skeletal effects of VCD-induced ovarian failure
to the effects of OVX. We hypothesized that BMD and
bone microarchitecture would be compromised because of
ovarian failure in both models, although the timing and
magnitude of changes would differ between VCD and
OVX animals because of the extended period of impending
ovarian failure (VCD) as well as the physiological impact of
residual ovarian tissue.
MATERIALS AND METHODS
Animals
C57Bl/6Hsd female mice were purchased from Harlan
Laboratories, housed in plastic cages, and maintained on
12L/12D cycles at 22 ± 2°C with food (Harlan Teklad 7013
NH-31 modified diet) and water available ad libitum. Ani-
mals were allowed to acclimate to the animal facility for 1
wk before initiation of treatment, after which they were
randomly assigned to treatment groups. For the first aim,
3-mo-old mice (n  6/group) were dosed daily with VCD
(160 mg/kg, IP) or sesame oil (vehicle control, IP) for 15
days and killed immediately after treatment to determine
whether VCD has direct short-term effects on bone micro-
architecture. For the second aim, 28-day-old animals were
dosed daily with VCD or vehicle control for 15 or 17 days
(n  6–7/group) and monitored using daily vaginal cytol-
ogy to determine ovarian failure. Surgical OVX was per-
formed on separate mice at 3 mo of age (n  8), which
corresponds to the age at which all VCD-treated mice had
undergone ovarian failure. All experiments were approved
by the University of Arizona IACUC and conformed to the
Guide for the Care and Use of Experimental Animals.
Vaginal cytology
Estrous cyclicity was determined by daily monitoring of
vaginal cytology after dosing with VCD or vehicle. Ovarian
failure in VCD-treated mice was assigned when vaginal cy-
tology indicated 15 days of persistent metestrus/diestrus
or diestrus.
(16)
BMD
In vivo BMD (g/cm
2) measurements of the lumbar spine
(L2–L4) were made using DXA (PIXImus; GELunar,
Madison, WI, USA) with animals under anesthesia (1.25%
Avertin).
Tissue collection
Animals were killed by CO2 inhalation at either 3 (for
the short-term treatment study) or 8.5 mo of age (for the
long-term study). Tibias and femurs from each animal were
collected, wrapped in saline-soaked gauze, and frozen at
−20°C. The remaining skeleton was fixed in 10% neutral
buffered formalin (NBF; 4°C; 48 h) and transferred to 70%
ethanol and stored at 4°C for CT evaluation. Ovaries were
collected from VCD-treated and cycling control animals.
Uteri, kidneys, adrenals, spleen, liver, lung, heart, brain,
intestine, and pituitary tissue from control, OVX, and
VCD-treated mice were collected, weighed, and fixed for
histopathological evaluation.
Evaluation of bone microarchitecture by µCT
Femurs and vertebrae were evaluated using a desktop
CT imaging system (CT40; Scanco Medical AG, Bass-
ersdorf, Switzerland) equipped with a 10-mm focal spot mi-
crofocus X-ray tube, as previously described.
(25) Transverse
CT slices of the distal femoral metaphysis, vertebral body
(L5), and femoral midshaft were acquired using 12-m iso-
tropic voxel size. Images were reconstructed, filtered, and
thresholded using a specimen-specific threshold, and mor-
phometric parameters were computed using a direct 3D
approach that does not rely on any assumptions about the
underlying structure.
(26–30) For trabecular morphology, the
following variables were assessed: bone volume fraction
(BV/TV, %), trabecular thickness (TbTh, m), trabecular
separation (TbSp, m), trabecular number (TbN, 1/mm),
connectivity density (ConnD, 1/mm
3), and structure model
index (SMI). For cortical bone, the following variables were
assessed: total area (mm
2), bone area (mm
2), medullary
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2), cortical bone volume fraction (BA/TA, %),
and cortical thickness (CortThick, m).
Hormone assays
Plasma 17-estradiol and androstenedione were deter-
mined by Coat-A-Count RIAs 3 wk and 2 mo after ovarian
failure/OVX, respectively (Diagnostic Products, Los Ange-
les, CA, USA).
Data analysis
Differences between groups and over time within groups
were analyzed by one-way ANOVA. Posthoc tests (Fisher’s
protected least significant difference) were used where ap-
propriate. All analyses were performed using Instat soft-
ware (Graphpad, San Diego, CA, USA). Differences were
considered significant at p < 0.05.
RESULTS
Short-term effects of VCD on bone
Two-weeks of VCD treatment had no direct effect on
bone morphology, because bone microarchitecture in the
vertebrae, distal femur, and femoral midshaft was not dif-
ferent between VCD and vehicle-treated mice killed imme-
diately after VCD dosing (before ovarian failure; data not
shown). Thus, these two groups were combined to form a
young (3 mo old) control group (n  12).
Ovarian failure
Immature (28 day old) mice dosed daily with VCD ex-
hibited ovarian failure at a mean of 48.1 ± 2.7 days after the
onset of dosing, with a range of 38–64 days. Vehicle-treated
control animals exhibited regular estrous cycles throughout
the course of the experiment (4.7 ± 0.3 days/cycle).
BMD
Lumbar spine BMD (SpBMD) was monitored by DXA
at time points between 1 and 4 mo after ovarian failure
for VCD-treated animals or after OVX for OVX animals
(Fig. 1). Relative to vehicle-treated controls, SpBMD was
significantly lower in OVX mice as early as 1 mo after
surgery (p < 0.05). SpBMD remained significantly lower
than control animals throughout the course of the experi-
ment until 4 mo after OVX (corresponding to 7 mo of age),
at which time vehicle-treated controls began to experience
a decline in bone mass. In contrast to this early and persis-
tent decrease in SpBMD in OVX animals, VCD-treated
animals experienced a slower decline in SpBMD relative to
vehicle-treated control animals, and SpBMD was only dif-
ferent from controls at 3 mo after ovarian failure (p < 0.05).
At 4 mo after ovarian failure or OVX, SpBMD was not
different between the groups.
Bone microarchitecture
Approximately 5.3 mo after ovarian failure/OVX (i.e.,
8.5 mo of age), vertebral trabecular BV/TV, TbN, and
ConnD were decreased (p < 0.01), and TbSp was increased
(p < 0.01) in both VCD-treated and OVX mice relative to
vehicle-treated age-matched controls (Table 1; Fig. 2). In
the distal femur, TbN was decreased (p < 0.01) and TbSp
increased (p < 0.001) in OVX relative to controls, whereas
no change was detected in the VCD-treated group relative
to vehicle-treated controls. Moreover, in the OVX group,
TbSp was increased (p < 0.05) relative to VCD-treated ani-
mals in both trabecular compartments.
No changes were detected at the femoral midshaft in
VCD-treated animals relative to vehicle-treated age-
matched controls (Table 1; Fig. 3). In contrast, in OVX
animals, cortical bone area, bone area fraction, and thick-
ness were reduced relative to VCD-treated and vehicle-
treated controls (p < 0.05 for all).
To assess underlying age-related changes, we compared
the young (3 mo old) control group to the vehicle-treated
group killed at ∼8.5 mo of age. Aging was associated with
significant trabecular bone deterioration. However, com-
pared with young controls, midfemoral size and cortical
bone area and thickness were higher in the older VCD- and
vehicle-treated mice but not OVX mice (Table 2; Fig. 3).
Circulating androstenedione levels
Circulating androstenedione levels were not different be-
tween control and VCD-treated animals 2 mo after ovarian
failure (Fig. 4). In contrast, androstenedione levels in OVX
animals 2 mo after OVX were significantly lower than both
control (−97%, p < 0.001) and VCD animals (−95%, p <
0.01).
Circulating 17-estradiol levels
Circulating levels of 17-estradiol in VCD-treated and
OVX mice were reduced by >50% compared with cycling
controls 3 wk after ovarian failure or OVX (Fig. 5). Termi-
nal (8.5 mo of age) 17-estradiol levels were undetectable
in both VCD and OVX groups (data not shown).
Tissue weights
The effect of VCD dosing and OVX on tissue weights
was determined at the time of skeletal collection and ex-
pressed as percent of total body weight (Table 3). Consis-
FIG. 1. Temporal changes in SpBMD in VCD-treated vs. OVX
mice assessed by DXA (values  mean ± SE, n  5–10/group).
Female C57Bl/6Hsd mice were dosed daily with vehicle control or
VCD (16.0 mg/kg/d). A subset of control animals underwent OVX
corresponding to the time of VCD-induced ovarian failure. Dif-
ferent letters (a, b, or c) represent different (p < 0.05) mean
values.
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deficiency, both OVX and VCD-treated animals had in-
creased body weight relative to controls, although this
reached statistical significance only in the VCD-treated
mice (p < 0.05). There was no difference between tissue
weight of adrenals, spleen, kidneys, or liver between ve-
hicle-treated controls, OVX, and VCD-treated animals.
Ovarian weights were decreased in VCD-treated animals
relative to controls (p < 0.0001), and uterine weights were
decreased in both OVX and VCD-treated groups relative
to controls (p < 0.001 and p < 0.01, respectively). Uterine
weights in OVX animals were also lower (p < 0.05) than in
VCD-treated animals. Histopathological evaluation of
OVX and VCD-treated animals confirmed morphological
evidence of uterine atrophy. Importantly, there were no
pathological effects observed microscopically in uteri, kid-
TABLE 1. BONE MICROARCHITECTURE AT THE LUMBAR SPINE,D ISTAL FEMUR, AND FEMORAL MIDSHAFT,A SSESSED BY CT
Control (n = 7) VCD (n = 6) OVX (n = 8)
p
Con vs. VCD Con vs. OVX VCD vs. OVX
Lumbar spine
BV/TV (%) 18.2 ± 0.74 14.6 ± 0.49 14.8 ± 0.57 <0.01 <0.01 NS
TbTh (m) 60.3 ± 0.76 59.7 ± 0.91 59.1 ± 0.76 NS NS NS
TbSp (m) 317 ± 7.03 365 ± 9.86 406 ± 12.6 <0.01 <0.01 <0.05
TbN (mm
-1) 3.16 ± 0.08 2.74 ± 0.06 2.49 ± 0.07 <0.01 <0.01 NS
ConnD (1/mm
3) 68.1 ± 5.08 43.7 ± 3.80 40.9 ± 4.09 <0.01 <0.01 NS
SMI 1.03 ± 0.11 1.4 ± 0.12 1.06 ± 0.09 <0.05 NS NS
Distal femur
BV/TV (%) 2.01 ± 0.22 1.73 ± 0.24 1.65 ± 0.25 NS NS NS
TbTh (m) 52.2 ± 1.78 52.4 ± 2.30 54.9 ± 1.15 NS NS NS
TbSp (m) 540 ± 6.63 586 ± 24.6 707 ± 76.2 NS <0.001 <0.05
TbN (mm
-1) 1.85 ± 0.02 1.72 ± 0.07 1.49 ± 0.15 NS <0.01 NS
ConnD (1/mm
3) 5.08 ± 1.04 4.00 ± 2.06 2.24 ± 0.61 NS NS NS
SMI 3.71 ± 0.13 3.72 ± 0.13 3.21 ± 0.17 NS NS NS
Femoral midshaft
Total area (mm
2) 1.84 ± 0.02 1.83 ± 0.03 1.78 ± 0.02 NS NS NS
Bone area (mm
2) 0.83 ± 0.01 0.80 ± 0.02 0.70 ± 0.03 NS <0.001 <0.001
Med. area (mm
2) 1.00 ± 0.02 1.03 ± 0.04 1.08 ± 0.02 NS NS NS
BA/TA (%) 45.4 ± 0.5 43.8 ± 1.20 39.4 ± 1.27 NS <0.001 <0.05
CortThick. (m) 194 ± 2.3 185 ± 5.0 162 ± 6.9 NS <0.001 <0.01
Values are mean ± SE.
NS, not significant.
FIG. 2. Trabecular bone architecture at the
fifth lumbar vertebral body and distal femo-
ral metaphysis in old (age 8.5 mo) and young
(age 3 mo) female C57Bl/6Hsd mice assessed
by CT (values mean ± SE, n 6–12/group).
Animals were dosed daily with vehicle control
or VCD (160 mg/kg/d). Old VCD and OVX
animals were 5.3 mo postovarian failure or
ovariectomy. The following variables were as-
sessed for trabecular morphology: bone vol-
ume fraction (BV/TV, %), trabecular thick-
ness (TbTh, m), trabecular separation
(TbSp, m), trabecular number (TbN, 1/mm),
connectivity density (ConnD, 1/mm
3), and
structure model index (SMI). Different letters
(a, b, or c) represent different (p < 0.05) mean
values.
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pituitary tissues from VCD-treated mice.
DISCUSSION
The overall purpose of this study was to compare skeletal
effects of ovarian failure in a chemically induced mouse
model of menopause (VCD treatment) with those seen
in ovariectomized (OVX) mice. The first aim was to evalu-
ate short-term effects of VCD treatment on trabecular or
cortical bone microarchitecture. CT measurements in
3-mo-old mice killed immediately after the completion of
15 days of VCD dosing showed that there were no direct
effects of VCD treatment on bone microarchitecture. Ad-
ditionally, based on assessment of tissue weights and histo-
pathological evaluation at necropsy, there were no effects
of VCD or OVX on tissues other than the ovary and uterus
or the uterus, respectively. The loss of ovarian weight in
VCD-treated animals can be attributed to ovarian failure,
whereas the loss of uterine weight in VCD-treated and
OVX animals can be attributed to loss of uterotropic effects
of 17-estradiol.
(15) Thus, the bone-related effects seen in
this study in VCD-treated animals are most likely the result
of loss of ovarian function rather than any direct toxic ef-
fects of VCD on bone.
C57Bl/6Hsd mice dosed with VCD underwent ovarian
failure on an average of 48 days after the onset of dosing (as
defined by 15-day persistent diestrus). As expected, both
OVX and VCD-treated animals had reduced 17-estradiol
3 wk after either surgery or chemical induced ovarian fail-
ure. Loss of estrogen’s bone protective effects leads to a
decline in bone mass in women after menopause.
(31,32)
FIG. 3. Midfemoral cortical bone in old
(age 8.5 mo) and young (age 3 mo) in female
C57Bl/6Hsd mice, assessed by CT (values 
mean ± SE, n  6–12/group). Animals were
dosed daily with vehicle control or VCD (160
mg/kg/d). Old VCD and OVX animals were
5.3 mo postovarian failure or ovariectomy.
For cortical bone, the following variables
were assessed: total area (mm
2), bone area
(mm
2), cortical bone volume fraction (BA/TA,
%), and cortical thickness (CortThick, m).
Different letters (a, b, or c) represent differ-
ent (p < 0.05) mean values.
TABLE 2. BONE MICROARCHITECTURE AT THE LUMBAR SPINE,
DISTAL FEMUR, AND FEMORAL MIDSHAFT IN YOUNG (3 MO) VS.
OLD (8.5 MO)M ICE,A SSESSED BY CT
Young
control (n = 12)
p
Old
Control
Old
VCD
Old
OVX
Lumbar spine
BV/TV (%) 26.1 ± 0.44 <0.001 <0.001 <0.001
TbTh (m) 55.8 ± 0.63 <0.001 <0.01 <0.05
TbSp (m) 219 ± 3.3 <0.001 <0.001 <0.001
TbN (mm
-1) 4.46 ± 0.06 <0.001 <0.001 <0.001
ConnD (1/mm
3) 173 ± 4.16 <0.001 <0.001 <0.001
SMI 0.67 ± 0.05 <0.05 <0.001 <0.01
Distal femur
BV/TV (%) 11.6 ± 0.34 <0.001 <0.001 <0.001
TbTh (m) 52.6 ± 0.50 NS NS NS
TbSp (m) 236 ± 3.4 <0.001 <0.001 <0.001
TbN (mm
-1) 4.20 ± 0.06 <0.001 <0.001 <0.001
ConnD (1/mm
3) 84.1 ± 4.76 <0.001 <0.001 <0.001
SMI 3.05 ± 0.05 <0.001 <0.001 NS
Femoral midshaft
Total area (mm
2) 1.66 ± 0.03 <0.001 <0.001 <0.05
Bone area (mm
2) 0.66 ± 0.01 <0.001 <0.001 NS
Med. area (mm
2) 1.00 ± 0.02 NS NS NS
BA/TA (%) 39.6 ± 0.46 <0.001 <0.01 NS
CortThick. (m) 158 ± 2.06 <0.001 <0.001 NS
Values are mean ± SE.
NS, not significant.
FIG. 4. Effect of VCD-induced ovarian failure or OVX on cir-
culating androstenedione levels in female C57Bl/6Hsd mice 2 mo
after ovarian failure or ovariectomy (values  mean ± SE, n 
5/group). Animals were dosed daily with vehicle control or VCD
(160 mg/kg/d). Circulating levels of androstenedione were mea-
sured by RIA (**p < 0.01; ***p < 0.001).
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1 mo after ovariectomy, whereas SpBMD in VCD-treated
animals was not reduced to that level for 2.5 more months.
Thus, despite ovarian failure and subsequently low levels of
circulating 17-estradiol, VCD-treated animals did not ex-
perience as rapid a decline in SpBMD as seen in OVX
animals.
Whereas both VCD-induced ovarian failure and OVX
led to a significant deterioration of trabecular bone micro-
architecture, there was a trend for greater and more con-
sistent declines in OVX versus VCD-treated mice. Further-
more, cortical bone at the femoral midshaft was preserved
in VCD-treated mice, whereas OVX mice showed signifi-
cant cortical bone loss compared with age-matched con-
trols.
Androstenedione may provide insight into the slower
and less dramatic loss of bone integrity in the VCD model
for natural menopause. Two months after ovarian failure,
circulating androstenedione levels remained normal and
significantly higher in VCD-treated animals relative to
OVX animals. As the mammalian ovary loses follicles by
ovulation or atresia, theca interna cells transition into in-
terstitial cells responsible for the production of andro-
gens.
(33) Previous studies have shown that residual ovarian
tissue in the follicle-deplete, VCD-treated mouse produces
androstenedione,
(14) a hormone known to preserve bone
mass in the rodent skeleton by restraining effects on osteo-
blastogenesis and osteoclastogenesis.
(34,35) Thus, continued
production of androgens after ovarian failure in the VCD-
treated group is likely responsible for the more gradual
decline in SpBMD over time, a hormone profile similar to
that seen over the course of the natural human peri- and
postmenopausal transition. It has recently been confirmed
that the human postmenopausal ovary produces androgens
well after menopause.
(36) Therefore, in this regard, the
VCD-treated mouse more appropriately mimics natural
menopause than the OVX model.
At 4 mo after ovarian failure/OVX for treatment groups,
animals were ∼6 mo of age, and SpBMD began to decline in
control animals. Relative to young mice, the aged vehicle-
treated control animals had also experienced a significant
loss in vertebral and femoral bone microarchitecture over
the course of the study, despite normal estrous cyclicity.
Recent studies have shown that female C57Bl/6J mice ex-
perience a steady decline in trabecular bone beginning at
2–3 mo of age and that deterioration in trabecular bone
architecture is more severe in the metaphyseal region of
long bones than in the vertebral body.
(25,37) Thus, failure to
observe drastic differences between OVX and VCD treat-
ment in older animals in this study, particularly in the distal
femur, was likely the result of ongoing age-related skeletal
deterioration that muted the effects of VCD treatment or
OVX.
Increased circulating FSH levels are seen during peri-
and postmenopause in women because of loss of negative
feedback on the anterior pituitary by ovarian steroids and
inhibin.
(1) Increasing FSH, therefore, is used as an early
predictor that precedes the onset of menopause. It has been
hypothesized that increased loss of bone mass seen in
menopausal women is because of direct effects of FSH on
bone.
(9,38) The proposed mechanism is through FSH stimu-
lation of TNF production by bone marrow granulocytes
and macrophages. This increase in TNF expands the num-
ber of bone marrow osteoclast precursors resulting in hy-
pogonadal bone loss. In the VCD-treated murine model of
menopause, we have previously shown that circulating FSH
levels increase before ovarian failure after the onset of dos-
ing in mice.
(14,15) In this study, SpBMD loss was not de-
tected until 2.9 mo after ovarian failure, which corresponds
to day 154 after the onset of dosing. Therefore, these find-
ings suggest that exposure of murine bone to 4 mo of in-
creased circulating FSH does not directly cause loss of bone
integrity. BMD measurements by DXA, however, may not
be sufficiently sensitive to detect early changes in trabecular
bone microarchitecture. Biochemical markers of bone turn-
over may be useful in this regard.
One shortcoming of this study is that direct, short-term
effects of VCD on bone microarchitecture was evaluated in
animals that were 3 mo of age, whereas ovarian failure was
induced with VCD in mice that were 28 days old at the start
of dosing. It is possible that the skeleton of young, growing
animals may respond differently to VCD than the skeleton
of mature, 3-mo-old animals. Additionally, the fact that we
waited several months after ovarian failure to assess bone
microarchitecture meant that mice had undergone signifi-
cant age-related bone loss by that time, as clearly seen in
comparisons between the young and old control animals.
FIG. 5. Effect of VCD-induced ovarian failure or OVX on cir-
culating 17-estradiol levels in female C57Bl/6Hsd mice 3 wk af-
ter ovarian failure or OVX (values  mean ± SE, n  5/group).
Animals were dosed daily with vehicle control or VCD (160 mg/
kg/d). Circulating levels of 17-estradiol were measured by RIA.
TABLE 3. TISSUE WEIGHTS EXPRESSED AS PERCENT OF TOTAL
BODY WEIGHT
Control VCD OVX
Body weight (g) 27.5 ± 1.0 33.6 ± 1.9* 32.0 ± 2.9
†
Ovary 0.027 ± 0.002 0.006 ± 0.002*
Uterus 0.354 ± 0.038 0.171 ± 0.037* 0.038 ± 0.005*
Adrenal 0.029 ± 0.003 0.021 ± 0.003 0.022 ± 0.002
Spleen 0.268 ± 0.01 0.233 ± 0.02 0.321 ± 0.03
Kidney 1.078 ± 0.03 0.986 ± 0.05 1.042 ± 0.09
Liver 4.432 ± 0.13 4.123 ± 0.27 4.806 ± 0.14
n  6–11/group.
* Different (p < 0.01) than control animals.
† Different (p < 0.05) than VCD-treated animals.
EFFECT OF VCD ON SKELETAL INTEGRITY IN MICE 1301Despite this complication, we were still able to detect sig-
nificant differences in bone microarchitecture in VCD-
treated and OVX animals that can likely be attributed to
loss of ovarian function because control animals were still
cycling.
To confirm that VCD’s negative impact on bone could be
attributed exclusively to ovarian failure, our laboratory pre-
viously conducted a study in which the effects of VCD
treatment and VCD treatment + subcutaneous E2 pellets
on BMD and bone microarchitecture were evaluated in
mice.
(39) Similar to the findings in this study, VCD-treated
mice had significantly lower femoral BMD, lower vertebral
trabecular BV/TV and number, and increased trabecular
separation relative to vehicle-treated mice. Consistent with
previous reports of anabolic effects of estrogen in mice,
(40–45)
VCD + E had increased femoral BMD, and markedly im-
proved trabecular bone parameters at the vertebrae and
distal femur compared with both VCD- and vehicle-treated
animals. These initial findings showed that VCD-induced
ovarian failure caused bone deterioration, and effects of
VCD treatment on bone could be reversed with exogenous
estrogen administration. Furthermore, it confirmed the
need for a direct comparison of the skeletal effects of VCD-
induced ovarian failure to that of OVX, as reported in this
study.
In summary, our results showed that VCD treatment
does not have direct effects on bone, and that, as a result of
chemically induced ovarian failure, bone mass and micro-
architecture are compromised in the VCD-treated murine
model for peri- and postmenopause. Compared with the
OVX model for menopause, skeletal changes in the VCD
model appear more slowly and are of lower magnitude.
These differences are most likely caused by the more physi-
ological approximation of natural menopause with gradual
onset of ovarian failure (model for perimenopause) and
retention of androgen-producing residual ovarian tissue
(model for postmenopause) after ovarian failure in VCD-
treated animals. These findings indicate that the VCD
model may be quite useful for future studies related to
menopause-associated bone disease, including both the
perimenopausal and postmenopausal periods. Although
the OVX model is limited in relevance for natural peri- and
postmenopause, it is useful for the assessment of potential
treatments for osteopenia in hypogonadal animals caused
by the resultant accelerated bone loss that can be achieved
in a relatively short amount of time. Thus, both surgical
(OVX) and natural (VCD) menopause models bring unique
strengths to the study of estrogen deficiency on skeletal in-
tegrity, and future studies using these combined models
might be useful for producing a complementary approach.
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